Investors in Pro Medicus Ltd (ASX: PME) shares have been on a wild ride.
The healthcare tech stock is down 6% over the past five days, yet still up 19% over the past month. Zoom out further, and it's a different story, as shares have fallen more than 50% over the past six months. Hectic is one word for it.
So what's really going on?
Image source: Getty Images
Landing new contracts
Start with the fundamentals. Pro Medicus remains a high-quality business. Its imaging software platform is widely used by hospitals and radiology groups, particularly in the US, and continues to win new contracts. The company benefits from a sticky customer base, high margins, and strong recurring revenue once systems are embedded.
The long-term growth story is still intact. Demand for advanced imaging solutions continues to rise, and Pro Medicus shares are well positioned to capture that trend. It's also expanding within existing customers, which can drive incremental revenue without the need for entirely new deals.
Broad market de-rating
So why the share price volatility? The main culprit is sentiment, not operations.
High-growth healthcare and tech stocks have been hit by a broad market de-rating, and Pro Medicus has been caught in the crossfire. Even after the sell-off, the stock still trades on a price-to-earnings ratio above 60, leaving it sensitive to any shift in investor expectations.
That dynamic has flowed through to broker views. Morgans recently retained its buy rating but trimmed its price target to $210, which suggests a 50% upside at the time of writing. The broker adjusted its model to reflect more conservative growth assumptions, including slower implementation revenue and updated currency settings. Even so, it maintained that the underlying business remains strong and long-term demand is intact.
More broadly, analyst sentiment remains favourable. According to TradingView data, 11 out of 15 brokers rate the stock as a buy or strong buy. The average 12-month price target sits at $194.38, implying around 38% upside, while the most bullish forecasts suggest gains of up to 75%.
Valuation risk
Still, risks remain. Valuation is the big one. Even after a sharp pullback, Pro Medicus shares continue to trade at a premium to most ASX stocks. That leaves less margin for error if growth slows or expectations aren't met.
Execution is also key. Investors are closely watching the pace of contract wins and how quickly those deals translate into revenue. Any delays or weaker-than-expected growth could weigh on sentiment further.
Foolish Takeaway
Pro Medicus remains a high-quality growth company, but it's also a stock driven heavily by expectations. When sentiment is strong, it can rally quickly. When it shifts, the downside can be just as sharp.
For now, the business looks solid. The price of Pro Medicus shares, however, may continue to be anything but.
